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We report phosphorylated and ubiquitinated aggregates of TAR DNA binding protein of 43 kDa (TDP-
43) in SH-SY5Y cells similar to those in brains of amyotrophic lateral sclerosis (ALS) and frontotem-
poral lobar degeneration with ubiquitinated inclusions (FTLD-U). Two candidate sequences for the
nuclear localization signal were examined. Deletion of residues 78–84 resulted in cytoplasmic local-
ization of TDP-43, whereas the mutant lacking residues 187–192 localized in nuclei, forming unique
dot-like structures. Proteasome inhibition caused these to assemble into phosphorylated and ubiq-
uitinated TDP-43 aggregates. The deletion mutants lacked the exon skipping activity of cystic ﬁbro-
sis transmembrane conductance regulator (CFTR) exon 9. Our results suggest that intracellular
localization of TDP-43 and proteasomal function may be involved in inclusion formation and neu-
rodegeneration in TDP-43 proteinopathies.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Frontotemporal lobar degeneration with ubiquitinated
inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS) are
well-known neurodegenerative disorders. FTLD is the second
most common form of cortical dementia in the population below
the age of 65 years [1]. ALS is the most common of the motor
neuron diseases, being characterized by progressive weakness
and muscular wasting, resulting in death within a few years.
Ubiquitin (Ub)-positive inclusions were found as a pathological
hallmark in brains of patients with FTLD-U and ALS, as well as
in Alzheimer’s disease (AD) and Parkinson’s disease (PD). Re-
cently, TAR DNA binding protein of 43 kDa (TDP-43) has beenchemical Societies. Published by E
eneration with ubiquitinated




onaka), masato@prit.go.jpidentiﬁed to be a major protein component of ubiquitin-positive
inclusions in FTLD-U and ALS brains [2,3]. TDP-43 was ﬁrst iden-
tiﬁed as a cellular factor that binds to the TAR DNA of HIV type 1
[4], and was also identiﬁed independently as part of a complex
involved in inhibition of the splicing of the cystic ﬁbrosis trans-
membrane conductance regulator (CFTR) gene [5]. TDP-43 aggre-
gates in neuronal cytoplasm and nuclei in a variety of
neurodegenerative disorders, which are now collectively referred
to as TDP-43 proteinopathies. For understanding molecular path-
ogenesis and evidence-based therapies for TDP-43 proteinopa-
thies, it is necessary to study the molecular mechanisms of
aggregation of TDP-43.
To elucidate these issues, in this study, we have established
the cellular models for intracellular aggregates of TDP-43 similar
to those in brains of TDP-43 proteinopathies patients. Expression
of deletion mutants of TDP-43 lacking two candidate sequences
for the nuclear localization signal (NLS), residues 78–84 or
187–192, resulted in the formation of Ub- and phosphorylated
TDP-43-positive cytoplasmic inclusions in the presence of a pro-
teasome inhibitor. These results suggest that intracellular locali-
zation of TDP-43 and proteasomal function may be involved in
the pathological process of TDP-43 proteinopathies.lsevier B.V. All rights reserved.
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2.1. Construction of plasmids
The PCR product of the open-reading frame of human TDP-43
using pRc-CMV-TDP-43 as a template was subcloned into themam-
malian expression vector pcDNA3 (Invitrogen) using restriction
sites BamH I and Xba I, creating pcDNA3-TDP-43. To construct plas-
mids of the deletion mutants, we used a site-directed mutagenesis
kit (Strategene). PCR was performed using the forward primer (50-
GTATGTTGTCAACTATATGGATGAGACAGATGC-30) and the reverse
primer (50-GCATCTGTCTCATCCATATAGTTGACAACATAC-30) for the
deletion mutant of 78–84 residues (DNLS), and the forward primer
(50-GCAAAGCCAAGATGAGGTGTTTGTGGGGCGC-30) and the reverse
primer (50-GCGCCCCACAAACACCTCATCTTGGCTTTGC-30) for the
deletion mutant of 187–192 residues (D187–192), with pcDNA3-Fig. 1. Subcellular localization of wild–type and mutant TDP-43 in SH-SY5Y cells. (A) Sche
and -2: blue) and glycine-rich domain (Gly-rich: red) are shown. (B–E) Immunostaining
TDP-43 (C), DNLS (D78–84) TDP-43 (D), and D187–192 TDP-43 (E) with anti-TDP-43 ant
merged image (right panel) are shown.TDP-43 as a template, respectively. For the construction of the dou-
ble-deletion mutantDNLS&187–192, PCR was performed using the
forward primer (50-GCAAAGCCAAGATGAGGTGTTTGTGGGGCGC-30)
and the reverse primer (50-GCGCCCCACAAACACCTCATCTTG
GCTTTGC-30) with pcDNA3-TDP-43DNLS as a template.
The reporter plasmid pSPL3-CFTR9 was constructed as follows.
Healthy human genomic DNA (a gift from Dr. Makoto Arai, Tokyo
Institute of Psychiatry, Japan) was subjected to PCR with the use
of the forward primer (50-CGGAATTCACTTGATAATGGGCAAA-
TATC-30) and the reverse primer (50-CCCTCGAGCTCGCCAT
GTGCAAGATACAG-30), containing EcoR I and Xho I sites, respec-
tively. The genomic region containing 221 bp of intron 8, the entire
exon 9 (183 bp), and 266 bp of intron 9 of the human CFTR gene
was ampliﬁed and digested with the two restriction enzymes, fol-
lowed by ligation into pSPL3 (Life Technologies), affording the plas-
mid pSPL3-CFTR9. All constructs were veriﬁed by DNA sequencing.matic diagram of the structural domains of TDP-43. RNA recognition motifs (RRM-1
of untransfected SH-SY5Y cells (B) and cells 72 h post transfection with wild-type
ibody (Left panel, green), nuclear staining by TO-PRO-3 (middle panel, blue) and the
Fig. 2. Expression of mutant TDP-43 followed by proteasome inhibition with MG132 results in the formation of intranuclear inclusions. Immunostaining of untransfected
cells (A) and cells 72 h post transfection with wild-type TDP-43 (B), DNLS (C), and D187–192 (D) followed by MG132 treatment (20 lM for 6 h) with anti-TDP-43 antibody
(left panel, green), nuclear staining by TO-PRO-3 (middle panel, blue) and merged image (right panel).
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A polyclonal TDP-43 antibody 10782-1-AP (anti-TDP-43) was
purchased from ProteinTech Group Inc. A polyclonal antibody spe-
ciﬁc for phosphorylated TDP-43 (anti-pS409/410) was prepared as
described [6]. Anti-ubiquitin monoclonal antibody (mAb),
MAB1510, was purchased from Chemicon. Monoclonal anti-HA
clone HA-7 were obtained from Sigma.
2.3. Cell culture and expression of plasmids
SH-SY5Y cells were cultured in DMEM/F12 medium (Sigma)
supplemented with 10% (v/v) fetal calf serum, penicillin–strepto-
mycin–glutamine (Gibco), and MEM non-essential amino acids
solution (Gibco). Cells were then transfected with expression
plasmids using FuGENE6 (Roche) according to the manufacturer’s
instructions. In the proteasome inhibition experiments, ﬁnal
1 lM MG132 (Peptide institute) in DMSO was added to the cul-
ture medium, and incubated overnight.
2.4. Confocal immunoﬂuorescence microscopy
SH-SY5Y cells were grown on a coverslip (15  15 mm) and
transfected with expression vector (1 lg). After incubation for theindicated time, the transfected cells on the coverslips were ﬁxed
with 4% (w/v) paraformaldehyde in phosphate-buffered saline
(PBS) for 30 min. The coverslips were then incubated with 0.2% (v/
v) Triton X-100 (TX) in PBS for 10 min. After blocking for 30 min in
5% (w/v) BSA in PBS, cells were incubated with anti-phosphorylated
TDP-43 antibody, pS409/410 (1:500 dilution), anti-TDP-43 (1:500),
anti-Ub (1:500) or anti-HA (1:500) for 1 h at 37 C, followed by FITC-
or TRITC-labeled goat anti-rabbit or-mouse IgG (Sigma, 1:500 dilu-
tion) as a secondary antibody for 1 h at 37 C. Afterwashing, the cells
were further incubated with TO-PRO-3 (Molecular Probes, 1:3000
dilution in PBS) for 1 h at 37 C to stain nuclear DNA, and analyzed
using a LSM5 Pascal confocal laser microscope (Carl Zeiss).2.5. Sequential extraction of proteins and immunoblotting
SH-SY5Y cells were grown in 6-well plates and transfected tran-
siently with expression plasmids (1 lg). After incubation for the
indicated time, cells were harvested and lysed in TS buffer
[50 mM Tris–HCl buffer, pH 7.5, 0.15 M NaCl, 5 mM ethylenedi-
aminetetraacetic acid, 5 mM ethylene glycol bis(b-aminoethyl
ether)-N,N,N,N-tetraacetic acid, and protease inhibitor cocktail
(Roche)]. Lysates were centrifuged at 290,000g for 20 min at
4 C, and the supernatant was recovered as the TS-soluble fraction.
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and centrifuged at 290,000g for 20 min at 4 C. The supernatant
was collected as TX-soluble fraction. TX-insoluble pellets were fur-
ther sonicated in TS buffer containing 1% (w/v) Sarkosyl (Sar), and
incubated for 30 min at 37 C. The mixtures were centrifuged at
290,000g for 20 min at room temperature, and the supernatant
was recovered as the Sar-soluble fraction. The remaining pellets
(insoluble in Sar) were lysed in SDS-sample buffer and heated for
5 min.
Each sample (10 or 20 lg) was separated by 12% (v/v) SDS–
PAGE using Tris–glycine buffer system, and proteins were trans-
ferred onto polyvinylidene diﬂuoride membrane (Millipore). The
blots were incubated overnight with the indicated primary anti-
body at an appropriate dilution (1:1000–3000) at room tempera-
ture, followed by the incubation with a biotin-labeled secondary
antibody. Signals were detected using an ABC staining kit (Vector).
2.6. CFTR exon 9 skipping assay
Cos-7 cells in 6-well plates were transfected with 0.5 lg of the
reporter plasmid pSPL3-CFTR9 plus 1 lg of pcDNA3 plasmid
encoding wild-type or its mutants, using FuGENE6. The cells were
harvested 48 h post transfection, and total RNA was extracted with
TRIzol (Invitrogen). The cDNA was synthesized from 1 lg of total
RNA with the use of the Superscript II system (Invitrogen). Primary
and secondary PCRs were carried out according to the instruction
manual of the exon trapping system (Life Technologies).Fig. 3. Immunocytochemical analyses of intracellular inclusion-like structures
formed in cells transfected with deletion mutants of TDP-43. SH-SY5Y cells 72 h
post transfection with wild-type, (A and B), D187–192 (C and D), DNLS (E and F),
and DNLS&187–192 (G and H) before (A, C, E, G) and after (B, D, F, H) treatment
with MG132 (20 lM for 6 h) were stained with a phosphorylation-speciﬁc
antibody, anti-pS409/410 (green), anti-ubiquitin (Ub: red) antibodies, and TO-
PRO-3 (blue).3. Results
3.1. Effect of deletion of two candidate NLS in TDP-43
Amino acid sequence containing proline followed by a cluster of
basic amino acids is known to be typical NLS. We found two such
sequences in TDP-43, PKDNKRK (residues 78–84) and PLRSRK (res-
idues 187–192) (Fig. 1A). To examine whether these sequences
function as the NLS, we constructed corresponding deletion mu-
tants of TDP-43 and expressed them in SH-SY5Y cells. We em-
ployed non-tagged TDP-43 plasmid for expression in cultured
cells, since expression of hemagglutinin (HA)-tagged TDP-43 in
SH-SY5Y cells caused formation of inclusion-like structures
(Fig. S1), suggesting that addition of the epitope tag to the N-termi-
nus may affect the conformation of TDP-43 and promote non-spe-
ciﬁc aggregate formation.
Endogenous TDP-43 expressed in the nucleus (Fig. 1B). Similar
but stronger nuclear TDP-43 staining was observed in cells
expressing wild-type TDP-43 (Fig. 1C), as compared with non-
transfected cells (Fig. 1B). When the deletion mutant lacking
residues 78–84 (DNLS) was transiently expressed, strong TDP-43
signals were detected in cytoplasm (Fig. 1D). This is reasonable be-
cause the sequence of 78–84 contains a part of the bipartite NLS in
TDP-43 recently identiﬁed by Winton et al. [7].
When the deletion mutant lacking residues 187–192 (D187–
192) was expressed, on the other hand, the mutant protein formed
dot-like structures in nuclei (Fig. 1E). This observation suggests
that this sequence does not function as a NLS.
3.2. Formation of intracellular TDP-43 inclusions in cultured SH-SY5Y
cells
Impaired Ub–proteasome system has been suggested in some
forms of neurodegenerative disease [8], and TDP-43 is indeed ubiq-
uitinated in the brains of patients with FTLD-U or ALS [3]. To exam-
ine whether impaired Ub–proteasome system is involved in
inclusion formation, we treated cells transfected with TDP-43wild-type or deletion mutants with a proteasome inhibitor,
MG132. In immunocytochemistry using phosphorylation-indepen-
dent anti-TDP-43 antibody, no obvious change in the localization
of TDP-43 was observed in mock cells (Fig. 2A), or in cells transfec-
ted with wild-type (Fig. 2B) or DNLS mutant (Fig. 2C) after MG132
treatment, as compared to those without MG132 (Fig. 1). In con-
trast, many round nuclear inclusions were generated in cells trans-
fected with D187–192 mutant after MG132 treatment (Fig. 2D:
12% of inclusion-positive cells).
Fig. 3 revealed the results of double immunostaining using anti-
pS409/410, phosphorylation-dependent anti-TDP-43 antibody [6],
and anti-Ub antibody. Cells expressing wild-type TDP-43 showed
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the presence or absence of MG132 (Fig. 3A and B). Cells transfected
with D187–192 showed small dot-like structures positive for anti-
pS409/410 antibody but negative for anti-Ub antibody without
MG132 treatment (Fig. 3C). Cells transfected with D187–192 after
the MG132 treatment contained inclusion-like structures in nuclei
that were intensely labeled with both antibodies (Fig. 3D: 8% of
inclusion-positive cells). Relatively large inclusions (5 lm) were
immunopositive for both antibodies, while small ones (<1 lm)
were positive for only phospho-speciﬁc TDP-43 antibody, suggest-Fig. 4. Immunoblot analyses of intracellular inclusions of deleted TDP-43 mutants in SH-
(WT) or TDP-43 deletion mutants, before (A and B) and after (C and D) treatment with MG
(TX) and 1% Sarkosyl (Sar), and these supernatants and the Sarkosyl-insoluble pellets (ppt
43 antibody (A and C) and anti-pS409/410 (B and D).ing that abnormal phosphorylation of TDP-43 is an early event in
the process of inclusion formation.
Cells transfected withDNLS showed no immunoreactivity with-
out MG132 treatment (Fig. 3E), but showed formation of cytoplas-
mic inclusions positive for both anti-pS409/410 and anti-Ub after
MG132 treatment (Fig. 3F: 10% of inclusion-positive cells). Fur-
thermore, cells transfected with mutant TDP-43 lacking both the
NLS and residues 187–192, named DNLS&187–192, formed intra-
cellular round inclusion-like structures positive for both anti-
pS409/410 and anti-Ub antibodies, independently of treatmentSY5Y cells. Untransfected cells (none) and cells 72 h post transfection with wild-type
132 (1 lMovernight), were sequentially extracted with Tris–saline (TS), 1% Triton-X
) were run on SDS–PAGE, transferred to PVDF membrane and probed with anti-TDP-
T. Nonaka et al. / FEBS Letters 583 (2009) 394–400 399with MG132 (Fig. 3G: 8% of inclusion-positive cells and H: 12%
of inclusion-positive cells). The inclusions were 10 lm in diame-
ter, being very similar in size to the neuronal cytoplasmic inclu-
sions found in patients with FTLD-U [2].
3.3. Immunoblot analysis of intracellular inclusions in the cultured cell
models
Cells expressing wild-type or mutant TDP-43 were sequentially
extracted, and the supernatants and pellets were analyzed by
immunoblotting. On analysis of cell lysates using anti-TDP-43 anti-
body, endogenous TDP-43 at 43 kDa was detected in all fractions.
Immunoreactivity of it was the strongest in TX-soluble fraction,
and was the weakest in Sar-insoluble fraction (black-lined arrow-
heads in Fig. 4A and C). A similar band pattern but with stronger
immunoreactivities was detected in cells transfected with wild-
type TDP-43 (WT).
The DNLS mutant TDP-43, which was detected as bands with
slightly lower molecular weight than that of the wild-type, was
also recovered mostly in the TS- and TX-soluble fractions
(Fig. 4A). The intensities of bands in the Sar-soluble and -insoluble
fractions were slightly increased after MG132 treatment (Fig. 4C).
Interestingly, these were positive for anti-pS409/410 (a black
arrowhead in Fig. 4D), suggesting that inhibition of proteasome
activity induces the aggregation of phosphorylated DNLS.
In contrast, expression of D187–192 mutant TDP-43, which was
detected as a band with almost the same molecular weight as that
of endogenous TDP-43, resulted in signiﬁcant increases in the Sar-
soluble and -insoluble (ppt) fractions as compared with those in
cells transfected with wild-type TDP-43 (Fig. 4A). Smeared and
higher-molecular-weight bands were also detected in the
Sar-soluble and -insoluble fractions (Fig. 4A). We also observed
pS409/410-positive bands in the Sar-soluble and -insoluble frac-
tions in the absence or presence of MG132 (white arrowheads in
Fig. 4B and D).Fig. 5. CFTR exon 9 skipping assay of the deletion mutants of TDP-43. (A) Schematic dia
sequence of TG11T7 in which the TG11 repeat is recognized by TDP-43, causing the CFTR
gene (60 and 117 bp, respectively: light grey boxes) ﬂanking CFTR exon 9 (183 bp: a dark
CFTR exon 9 (177 bp). (B) Gel electrophoresis of RT-PCR products of RNA from transfect
pSPL3-CFTR exon 9 plus pcDNA3 expression vectors were used as templates for RT-PCRFinally, immunoblots of lysates from cells expressing
DNLS&187–192 mutant TDP-43 (41 kDa bands marked with grey
arrowheads in Fig. 4A and C) showed high-molecular-weight bands
of 45 kDa (black arrowheads in Fig. 4A and C) and smears in the
Sar-soluble and -insoluble fractions. The bands of 45 kDa, smears,
and C-terminal fragments at 25–37 kDa were highly immunoreac-
tive with anti-pS409/410 antibody independently of MG132 treat-
ment (black-lined arrowheads in Fig. 4B and D). These were similar
characteristic band patterns to those found in immunoblot analy-
ses of brain lysates of FTLD-U and ALS as previously reported [6].
3.4. Deletion mutants of TDP-43 lost the exon skipping activity
To evaluate the functional signiﬁcance of the deletion mutants
of TDP-43 used in this study, we performed CFTR exon 9 skipping
assay. As shown in Fig. 5B, mRNA from cells transfected with
empty vector pcDNA3 gave only one RT-PCR band of 360 bp, while
that from cells transfected with pcDNA3-TDP-43 wild-type gave
two RT-PCR bands, 360 and 177 bp, showing that skipping of CFTR
exon 9 was increased by expression of wild-type TDP-43. In con-
trast, only one RT-PCR band of 360 bp was observed from cells
co-transfected with DNLS, D187–192, or DNLS&187–192, indicat-
ing that these mutants do not have skipping activity of CFTR exon
9, which is one of known physiological functions of TDP-43.
4. Discussion
In this study, using SH-SY5Y cells and a phosphorylated TDP-43
speciﬁc antibody established by ourselves, we examined the effect
of deletion of two candidate sequences for NLS, residues 78–84 and
187–192 of TDP-43, and proteasomal inhibition on inclusion for-
mation. Mislocalization of TDP-43 into cytoplasm caused by dele-
tion of residues 78–84 proves that this sequence indeed
functions as NLS. This result is largely consistent with the previous
report by Winton et al., which showed that residues 82–98 weregram of the reporter plasmid pSPL3-CFTR exon 9. This plasmid contains the repeat
exon 9 to be spliced out. The insert of this plasmid contains two exons of HIV-1 tat
grey box). RT-PCR is expected to generate two products with (360 bp) and without
ed cos-7 cells. The RNAs from cos-7 cells, co-transfected with the reporter plasmid
analysis. The products were analyzed by electrophoresis in 1.5% agarose gel.
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nuclear TDP-43 positive dot-like structures caused by deletion of
residues 187–192 suggests that this sequence does not function
as a NLS but is nonetheless important to maintain a physiological
state of TDP-43 in the nucleus. Loss of the exon skipping activity
of CFTR exon 9 observed in cells transfected with this mutant
may also support such a notion.
The results of the present study suggest that mislocalization of
TDP-43 in cytoplasm is not a sufﬁcient condition for aggregation of
TDP-43, since the treatment of MG132, a proteasomal inhibitor, is
needed to cause the formation of inclusion in cells transfected with
a mutant TDP-43 lacking residues 78–84. Proteasome inhibition
also induced formation of intranuclear inclusions in cells transfec-
ted with a mutant TDP-43 lacking residues 187–192. These results
also suggest that a proteasome activity plays an important role for
degradation of TDP-43. Impairment of the ubiquitin-proteasome
system has recently been suggested to be related to the onset of
neurodegenerative diseases. For instance, Bence et al reported that
intracellular aggregates of a huntingtin fragment containing a
pathogenic polyglutamine repeat directly impaired the function
of the ubiquitin-proteasome system [9]. Keck et al., showed that
proteasome was inhibited by paired helical ﬁlament-tau in brains
of patients with Alzheimer’s disease [10]. It should be further
investigated whether the proteasome activity is actually decreased
in brains of patients with TDP-43 proteinopathies, as Keller et al.,
reported that a signiﬁcant decrease in proteasome activity was ob-
served in AD brains [11]. Function of autophagy-lysosome degra-
dation system may be an issue to be investigated as well, since
inhibition of autophagic degradation by depletion of the endo-
somal sorting complexes required for transport (ESCRT) subunits
causes accumulation of TDP-43 in ubiquitinated inclusions in cul-
tured cells [12].
In contrast to a mutant lacking residues 78–84 or 187–192,
double-deletion mutant of these sequences caused inclusion for-
mation without proteasomal inhibition in this study. These results
suggest the possibility that the double mutant protein has a higher
propensity to aggregate than each single mutant protein. In this
context, it should be noted that in insoluble fraction from FTLD-
U brains, the amount of C-terminal fragments of TDP-43 is higher
than that of the full-length TDP-43 [6]. These ﬁndings suggest that
conformation or modiﬁcations of TDP-43 is another important fac-
tor for inclusion formation.
Importantly, intranuclear or cytoplasmic inclusions observed in
this study were immunopositive for both a phosphorylation-
dependent anti-TDP-43 antibody and anti-Ub antibody, suggesting
that those consist of phosphorylated and ubiquitinated TDP-43.
Biochemical analyses also support that abnormal phosphorylation
of TDP-43 takes place in cells with inclusions. These results suggest
that our cellular models recapitulate the phenotypes of TDP-43
proteinopathies both pathologically and biochemically. Thesemodels are expected to be valuable tools for understanding the
pathological process underlying TDP-43 proteinopathies and for
identifying candidate drugs to prevent intracellular aggregation
of TDP-43.
Acknowledgements
We thank Dr. M. Arai (Tokyo Institute of Psychiatry) for provid-
ing human genomic DNA, and Drs. H. Mimuro (University of Tokyo)
and F. Kametani (Tokyo Institute of Psychiatry) for helpful advice
and discussions. This work was supported by a Grant-in-Aid for
Scientiﬁc Research on Priority Areas-Research on Pathomecha-
nisms of Brain Disorders (to M.H., 20023038) and Grants-in-Aid
for Scientiﬁc Research (B) (to M.H., 18300117) and (C) (to T.N.,
19590297 and T.A., 19591024) from the Ministry of Education, Cul-
ture, Sports, Science and Technology of Japan.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.febslet.2008.12.031.
References
[1] Snowden, J.S., Neary, D. and Mann, D.M. (2002) Frontotemporal dementia. Brit.
J. Psychiatr. 180, 140–143.
[2] Arai, T. et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative
inclusions in frontotemporal lobar degeneration and amyotrophic lateral
sclerosis. Biochem. Biophys. Res. Commun. 351, 602–611.
[3] Neumann, M. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Science 314, 130–133.
[4] Ou, S.H., Wu, F., Harrich, D., Garcia-Martinez, L.F. and Gaynor, R.B. (1995)
Cloning and characterization of a novel cellular protein, TDP-43, that binds to
human immunodeﬁciency virus type 1 TAR DNA sequence motifs. J. Virol. 69,
3584–3596.
[5] Buratti, E., Dork, T., Zuccato, E., Pagani, F., Romano, M. and Baralle, F.E. (2001)
Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon
9 skipping. EMBO J. 20, 1774–1784.
[6] Hasegawa, M. et al. (2008) Phosphorylated TDP-43 in frontotemporal lobar
degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 64, 60–70.
[7] Winton, M.J., Igaz, L.M., Wong, M.M., Kwong, L.K., Trojanowski, J.Q. and Lee,
V.M. (2008) Disturbance of nuclear and cytoplasmic TAR DNA-binding protein
(TDP-43) induces disease-like redistribution, sequestration, and aggregate
formation. J. Biol. Chem. 283, 13302–13309.
[8] Giasson, B.I. and Lee, V.M. (2003) Are ubiquitination pathways central to
Parkinson’s disease? Cell 114, 1–8.
[9] Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin–
proteasome system by protein aggregation. Science 292, 1552–1555.
[10] Keck, S., Nitsch, R., Grune, T. and Ullrich, O. (2003) Proteasome inhibition by
paired helical ﬁlament-tau in brains of patients with Alzheimer’s disease. J.
Neurochem. 85, 115–122.
[11] Keller, J.N., Hanni, K.B. and Markesbery, W.R. (2000) Impaired proteasome
function in Alzheimer’s disease. J. Neurochem. 75, 436–439.
[12] Filimonenko, M. et al. (2007) Functional multivesicular bodies are required for
autophagic clearance of protein aggregates associated with neurodegenerative
disease. J. Cell Biol. 179, 485–500.
